Over the past 30 years, the majority of (pre) clinical efforts to find an effective therapy for
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …

Abstract Cerebral Amyloid Angiopathy (CAA) is a neurological disorder characterized by the
deposition of amyloid plaques in the walls of cerebral blood vessels. This condition poses …

Ageing increases susceptibility to neurodegenerative disorders, such as Alzheimer's
disease (AD). Serum levels of sclerostin, an osteocyte-derived Wnt–β-catenin signalling …

Alzheimer's Disease (AD) represents a complex interplay of neurological pathways and
molecular mechanisms, with significant impacts on patients' lives. This review synthesizes …

Alzheimer's disease (AD) is a neurodegenerative disorder that affects memory formation and
storage processes. Dysregulated neuronal calcium (Ca2+) has been identified as one of the …

Alzheimer's disease, a progressive neurodegenerative condition, is characterized by a
gradual decline in cognitive functions. Current treatment approaches primarily involve the …

Recent studies promote new interest in the intersectionality between autism spectrum
disorder (ASD) and Alzheimer's Disease. We have reported high levels of Amyloid-β …

Alzheimer's disease (AD) is an extremely complex and heterogeneous pathology influenced
by many factors contributing to its onset and progression, including aging, amyloid-beta (Aβ) …

From an epidemiological and pathophysiological point of view, Alzheimer's disease (AD)
and type 2 diabetes (T2DM) should be considered'sister'diseases. T2DM significantly …

Cerebrospinal fluid (CSF) phosphorylated tau231 (P‐tau231) is associated with
neuropathological outcomes of Alzheimer's disease (AD). The invasive access of …